Compare Medtronic PLC (MDT) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Petróleo Brasileiro SA — how do they compare? Medtronic PLC trades at $87.9 (market cap $109.38B), while Petróleo Brasileiro SA trades at $24.51 (market cap $149.03B). The key difference: Petróleo Brasileiro SA is the larger of the two by market cap, and Petróleo Brasileiro SA pays the higher dividend (6.98%). Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Petróleo Brasileiro SA for 25 Days on average.
| MDT | PBR | |
|---|---|---|
Market Cap | $109.38B | $149.03B |
Volume | 55,890,185 | 30,322,411 |
Sector | Health | Energy |
52-Week High | $105.35 | $24.69 |
52-Week Low | $73.75 | $11.54 |
Typical Hold Time | 63 Days | 25 Days |
Enterprise Value | $128.71B | $209.45B |
Dividend Yield | 3.37% | 6.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $85.51, down 1.81% on the day, showing bearish technical signals despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters with Q3 2026 results pending, while maintaining robust profitability margins of 65% gross and 14% net. Recent news highlights the company's 49-year dividend growth streak and new product approvals, though technical indicators show selling pressure with the stock trading near support at $85.
MDT presents a compelling value opportunity with a 3.2% dividend yield and 14% upside to the $97.80 consensus target, though near-term technical weakness and increasing debt levels warrant caution. The company's consistent earnings beats and medical device market leadership support long-term growth, while regulatory approvals for new systems provide catalysts.
Petrobras (PBR) trades at $23.99, up 0.8% with strong bullish technical signals from moving averages. The company shows robust fundamentals with a P/E of 6.06, net income margin of 24.52%, and ROE of 30.77%. Recent Q2 2026 earnings beat expectations at $1.62 EPS versus $1.52 expected. Positive developments include new oil discoveries and platform deployments boosting production capacity.
PBR presents compelling value with attractive valuation metrics and strong profitability, though current price sits near analyst consensus target of $22.33. Key risks include political interference in Brazil and capital expenditure pressures. The stock offers dividend yield potential with recent $0.53 dividend declaration, supported by 50% analyst buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
